Publicacións en colaboración con investigadores/as de Hospital de Jerez (23)

2024

  1. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

    The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

2021

  1. Epidemiology and prognosis of patients with a history of cancer admitted to intensive care. A multicenter observational study

    Medicina Intensiva, Vol. 45, Núm. 6, pp. 332-346

  2. Executive summary: Position document: Evaluation and management of hypoglycemia in the patient with diabetes mellitus 2020. Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition

    Endocrinologia, Diabetes y Nutricion, Vol. 68, Núm. 4, pp. 270-276

  3. Obstetric Outcomes of SARS-CoV-2 Infection in Asymptomatic Pregnant Women

    Viruses, Vol. 13, Núm. 1

  4. Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?

    Rheumatology (Oxford, England), Vol. 60, Núm. 11, pp. 5329-5336

  5. The association between SARS-CoV-2 infection and preterm delivery: a prospective study with a multivariable analysis

    BMC Pregnancy and Childbirth, Vol. 21, Núm. 1

2020

  1. First national survey of the diagnosis of Helicobacter pylori infection in Clinical Microbiology Laboratories in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 9, pp. 410-416

  2. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834

2019

  1. IHDIP: A controlled randomized trial to assess the security and effectiveness of the incremental hemodialysis in incident patients

    BMC Nephrology, Vol. 20, Núm. 1

  2. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients

    Annals of Hematology, Vol. 98, Núm. 2, pp. 321-330

2018

  1. Rationale and design of DiPPI: A randomized controlled trial to evaluate the safety and effectiveness of progressive hemodialysis in incident patients

    Nefrologia, Vol. 38, Núm. 6, pp. 630-638

2017

  1. Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma

    Cancer Medicine, Vol. 6, Núm. 12, pp. 2766-2774

2016

  1. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up

    Journal of the American College of Cardiology, Vol. 67, Núm. 11, pp. 1278-1285

  2. Characterization of patients with lupus nephritis included in a large cohort from the Spanish society of rheumatology registry of patients with systemic lupus erythematosus (RELESSER)

    Medicine (United States), Vol. 95, Núm. 9

  3. Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry

    Rheumatology (United Kingdom), Vol. 55, Núm. 7, pp. 1243-1250

2015

  1. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program

    American Journal of Hematology, Vol. 90, Núm. 5, pp. 429-433

2012

  1. Medida de la presión arterial en consulta y automatizada (BPTru®) para evaluar el efecto de bata blanca

    Medicina Clinica, Vol. 138, Núm. 14, pp. 597-601

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

  2. Staphylococcus spp. en España: Situación actual y evolución de la resistencia a antimicrobianos (1986-2006)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 26, Núm. 5, pp. 269-277